Avanir Pharmaceuticals, Inc. - Strategic SWOT Analysis Review

Avanir Pharmaceuticals, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Avanir Pharmaceuticals, Inc. (Avanir) a subsidiary of Otsuka America, Inc. is a biopharmaceutical company which focuses on developing medicines for patients suffering from central nervous system disorders. The company’s lead product includes NUEDEXTA (AVP-923), a first-in-class dual N-methyl-D-aspartate (NMDA) rector antagonist and sigma-1 agonist. The product is approved in the US and Europe for the treatment of pseudobulbar affect (PBA). Its ONZETRA Xsail is developed for the treatment of migraine with or without aura in adult and AVP-786 has been developed for the treatment of depression and schizophrenia. The company is also developing various products under pipeline for the treatment of CNS disorders. Avanir is headquartered in Aliso Viejo, California, the US.

Avanir Pharmaceuticals, Inc. Key Recent Developments

Jan 20, 2016: Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as President and Chief Executive Officer
Dec 01, 2015: Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect Symptoms and Use of Antipsychotic Medications in Nursing Homes
Jun 30, 2015: Rigel Welcomes Keith A. Katkin to Board of Directors

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Frequently Asked Questions